• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study.

作者信息

Januzzi James L, Omar Alaa Mabrouk Salem, Liu Yuxi, Murphy Sean, Butler Javed, Felker G Michael, Piña Iliana L, Ward Jonathan, Solomon Scott, Contreras Johanna

机构信息

Massachusetts General Hospital (J.L.J., Y.L., S.M.), Harvard Medical School, Boston.

Baim Institute for Clinical Research, Boston, MA (J.L.J.).

出版信息

Circulation. 2022 Nov 22;146(21):1638-1640. doi: 10.1161/CIRCULATIONAHA.122.061693. Epub 2022 Oct 2.

DOI:10.1161/CIRCULATIONAHA.122.061693
PMID:36183276
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9674443/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82bf/9674443/8a5dc7040f62/cir-146-1638-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82bf/9674443/8a5dc7040f62/cir-146-1638-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82bf/9674443/8a5dc7040f62/cir-146-1638-g001.jpg

相似文献

1
Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study.沙库巴曲缬沙坦起始治疗与射血分数降低的心力衰竭患者二尖瓣反流严重程度之间的关联：PROVE-HF研究
Circulation. 2022 Nov 22;146(21):1638-1640. doi: 10.1161/CIRCULATIONAHA.122.061693. Epub 2022 Oct 2.
2
Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.沙库巴曲缬沙坦（LCZ696）在日本射血分数降低的慢性心力衰竭患者中的疗效与安全性：随机双盲PARALLEL-HF研究的原理与设计
J Cardiol. 2017 Sep;70(3):225-231. doi: 10.1016/j.jjcc.2016.11.011. Epub 2016 Dec 24.
3
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.射血分数对沙库巴曲缬沙坦（LCZ696）治疗射血分数降低的心力衰竭的疗效及预后的影响：ARNI与ACEI对心力衰竭全球死亡率和发病率影响的前瞻性比较（PARADIGM-HF）试验
Circ Heart Fail. 2016 Mar;9(3):e002744. doi: 10.1161/CIRCHEARTFAILURE.115.002744.
4
The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.沙库巴曲缬沙坦治疗射血分数降低的心力衰竭的逆重构反应。
Cardiovasc Ther. 2018 Aug;36(4):e12435. doi: 10.1111/1755-5922.12435. Epub 2018 Jun 7.
5
Left ventricular reverse remodeling following initiation of sacubitril/valsartan for heart failure with reduced ejection fraction and low blood pressure.起始沙库巴曲缬沙坦治疗射血分数降低的心力衰竭并伴有低血压时的左心室逆向重构。
Heart Vessels. 2024 Feb;39(2):95-104. doi: 10.1007/s00380-023-02311-3. Epub 2023 Sep 21.
6
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.血管紧张素受体脑啡肽酶抑制剂治疗功能性二尖瓣反流。
Circulation. 2019 Mar 12;139(11):1354-1365. doi: 10.1161/CIRCULATIONAHA.118.037077.
7
Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.在波兰，心力衰竭伴有射血分数降低的患者中，应用新型药物（沙库巴曲缬沙坦）——血管紧张素受体脑啡肽酶抑制剂的初步临床经验。
Kardiol Pol. 2018;76(2):381-387. doi: 10.5603/KP.a2017.0230. Epub 2017 Dec 1.
8
Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?沙库巴曲缬沙坦的重构作用是否取决于心力衰竭持续时间？
J Cardiovasc Med (Hagerstown). 2020 Sep;21(9):682-687. doi: 10.2459/JCM.0000000000001000.
9
Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry.沙库巴曲缬沙坦在射血分数轻度降低或保留的心力衰竭患者中的应用：“遵循指南-心力衰竭”注册研究
Circ Heart Fail. 2023 Jan;16(1):e010176. doi: 10.1161/CIRCHEARTFAILURE.122.010176. Epub 2022 Oct 31.
10
Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.利钠肽与沙库巴曲缬沙坦治疗射血分数降低的心力衰竭。
JACC Heart Fail. 2021 Feb;9(2):127-136. doi: 10.1016/j.jchf.2020.09.013. Epub 2020 Nov 11.

引用本文的文献

1
Functional Mitral Regurgitation and the Role of Transcatheter Repair.功能性二尖瓣反流与经导管修复的作用
Struct Heart. 2024 Jul 31;9(7):100347. doi: 10.1016/j.shj.2024.100347. eCollection 2025 Jul.
2
Deep learning for echocardiographic assessment and risk stratification of aortic, mitral, and tricuspid regurgitation: the DELINEATE-regurgitation study.用于主动脉瓣、二尖瓣和三尖瓣反流的超声心动图评估及风险分层的深度学习：DELINEATE反流研究
Eur Heart J. 2025 Jul 21;46(28):2780-2791. doi: 10.1093/eurheartj/ehaf248.
3
Outcome Improvement with Last-Generation Devices in Mitral Transcatheter Edge-to-Edge Repair: Insights from the Real-World MitraClip Florence Registry.

本文引用的文献

1
Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.沙库巴曲缬沙坦治疗起始后N末端前B型利钠肽的变化与射血分数降低的心力衰竭患者心脏结构和功能的关联
JAMA. 2019 Sep 17;322(11):1085-1095. doi: 10.1001/jama.2019.12821.
2
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.血管紧张素受体脑啡肽酶抑制剂治疗功能性二尖瓣反流。
Circulation. 2019 Mar 12;139(11):1354-1365. doi: 10.1161/CIRCULATIONAHA.118.037077.
3
Transcatheter Mitral-Valve Repair in Patients with Heart Failure.
二尖瓣经导管缘对缘修复术中使用新一代器械的预后改善：来自真实世界MitraClip佛罗伦萨注册研究的见解
J Clin Med. 2025 Feb 8;14(4):1075. doi: 10.3390/jcm14041075.
4
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy.推荐的四大支柱心力衰竭药物治疗时代的心脏重塑
ESC Heart Fail. 2025 Apr;12(2):1029-1044. doi: 10.1002/ehf2.15095. Epub 2024 Nov 26.
5
COAPT Trial at 5 Years: Same Doubts Remain About the Efficacy of Transcatheter Edge-to-Edge in Functional Mitral Regurgitation.5年COAPT试验：经导管缘对缘修复治疗功能性二尖瓣反流的疗效仍存同样疑虑。
Braz J Cardiovasc Surg. 2024 Oct 17;39(4):e20230360. doi: 10.21470/1678-9741-2023-0360.
6
Atrial Functional Mitral Regurgitation: From Diagnosis to Current Interventional Therapies.心房功能性二尖瓣反流：从诊断到当前的介入治疗
J Clin Med. 2024 Aug 25;13(17):5035. doi: 10.3390/jcm13175035.
7
Myocardial Recovery in the Systemic Context: A Philosophic Shift for the Heart Failure Subspecialty to Optimize Patient Care.从整体角度看心肌恢复：心力衰竭亚专科优化患者治疗的哲学转变
Methodist Debakey Cardiovasc J. 2024 Aug 20;20(4):98-108. doi: 10.14797/mdcvj.1416. eCollection 2024.
8
2024 update in heart failure.2024年心力衰竭治疗进展
ESC Heart Fail. 2025 Feb;12(1):8-42. doi: 10.1002/ehf2.14857. Epub 2024 May 28.
9
Transient Left Ventricular Dysfunction from Cardiomyopathies to Myocardial Viability: When and Why Cardiac Function Recovers.从心肌病到心肌存活的短暂性左心室功能障碍：心脏功能何时恢复及为何恢复。
Biomedicines. 2024 May 9;12(5):1051. doi: 10.3390/biomedicines12051051.
10
Efficacy of early administration of sacubitril/valsartan after coronary artery revascularization in patients with acute myocardial infarction complicated by moderate-to-severe mitral regurgitation: a randomized controlled trial.冠状动脉血运重建术后急性心肌梗死后合并中重度二尖瓣反流患者早期应用沙库巴曲缬沙坦的疗效：一项随机对照试验。
Heart Vessels. 2024 Aug;39(8):673-686. doi: 10.1007/s00380-024-02398-2. Epub 2024 Apr 18.
经导管二尖瓣修复术治疗心力衰竭患者。
N Engl J Med. 2018 Dec 13;379(24):2307-2318. doi: 10.1056/NEJMoa1806640. Epub 2018 Sep 23.
4
Evolution of secondary mitral regurgitation.继发性二尖瓣反流的演变。
Eur Heart J Cardiovasc Imaging. 2018 Jun 1;19(6):622-629. doi: 10.1093/ehjci/jey023.
5
Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance.原发性瓣膜反流的非侵入性评估建议：美国超声心动图学会与心血管磁共振学会合作制定的报告
J Am Soc Echocardiogr. 2017 Apr;30(4):303-371. doi: 10.1016/j.echo.2017.01.007. Epub 2017 Mar 14.